Home » Newsletters » BioWorld Science

BioWorld Science

April 4, 2011

View Archived Issues

Combination of HER2 and VEGF peptidomimetics block angiogenesis and tumor cell growth

Atsttrin suppresses onset and symptoms of inflammatory arthritis in vivo

Immunohistochemical quantitation of LAMP-2 for the diagnosis of phospholipidosis

Superoxide dismutase [Cu-Zn] as a biomarker for drug-induced liver injury

Novel fluoroquinolone antibacterial agents patented by Achaogen

BioCryst presents new tyrosine-protein kinase JAK3 inhibitors

Novel HSP 90 inhibitors synthesized at Nerviano Medical Sciences

New inhibitors of dual specificity protein kinase TTK presented

Concert Pharma presents new deuterated xanthine derivatives

Dipraglurant enters phase IIa trial in Parkinson's disease and levodopa-induced dyskinesia

BARDA funds development of influenza therapy CS-8958

Metabolic Solutions Development begins phase IIa trial of MSDC-0602

Intercept Pharma reports phase II data on obeticholic acid in primary biliary cirrhosis

Polaris Pharma begins pivotal studies of ADI-PEG 20

Solvay to launch offer for Rhodia

MP-29-02 NDA filed in U.S. for seasonal allergic rhinitis

Eisai and PRISM collaborate on inhibitors of complex between CREB-binding protein and catenin beta-1

Ongoing phase II proof-of-concept trial evaluates LY-2828360 for osteoarthritic knee pain

IPI-926 reduces tumor growth in vivo and advances through clinical development

Lundbeck launches Sycrest in first European market

Algeta and Genzyme to collaborate on new approach to cancer treatment

QIAGEN reaches agreement to acquire Cellestis

Generex presents new strategic development plan

Anavex Life Sciences begins screening for phase I study of ANAVEX 2-73

Furiex Pharma evaluates PPD-10558 in phase II study in subjects with statin intolerance

Popular Stories

Today's news in brief
BioWorld
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
SERCA inhibitor from Sumitomo shows promise for MSA-C treatment
BioWorld Science
At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, Sumitomo Pharma Co....